Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 10/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.41 |
| ▸ | POLB | P06746 | 6/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | BLM | P54132 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18349199 | 0.86 | KMT2A (0.55) | RAB9ANPC1ACHEKMT2APOLB | |
| SCHEMBL18349255 | 0.78 | KMT2A (0.54) | RAB9ANPC1ACHEKMT2APOLB | |
| SCHEMBL19860014 | 0.78 | KMT2A (0.53) | RAB9ANPC1ACHEKMT2APOLB | |
| SCHEMBL18349222 | 0.76 | PTPN1 (0.41) | ACHEKMT2APOLB | |
| SCHEMBL18349215 | 0.74 | KMT2A (0.54) | RAB9ANPC1ACHEKMT2APOLB | |
| SCHEMBL18349243 | 0.72 | CYP19A1 (0.41) | RAB9ANPC1KMT2APOLBCYP19A1 | |
| SCHEMBL18349234 | 0.72 | CHAT (0.42) | RAB9ANPC1KMT2APOLBCYP19A1 | |
| Perchlorate SCHEMBL4878649 | 0.65 | KMT2A (0.64) | RAB9ANPC1ACHEKMT2APOLB | |
| Perchlorate SCHEMBL4878642 | 0.65 | KMT2A (0.64) | RAB9ANPC1ACHEKMT2APOLB | |
| SCHEMBL14609511 | 0.63 | UTS2R (0.61) | KMT2AMEN1LMNAHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890187-B2 | Prototype systems of theranostic biomarkers for in vivo molecular management of cancer | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD. (CY) | 2018-02-13 | — | — | US | disclosed |
| US-20160376298-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD (CY) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376298-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | TP53, MKI67, FLT3 | RAB9A 3409/4885NPC1 4408/4885ACHE 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.